.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,087,091

« Back to Dashboard

Details for Patent: 6,087,091

Title: Method of selecting a compound for producing analgesia
Abstract:A method of producing analgesia in nociceptive and neuropathic pain is disclosed. The method includes administering to a subject an omega conopeptide which is characterized by its ability to (a) inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind selectively to omega conopeptide MVIIA binding sites present in neuronal tissue. Also disclosed are novel omega conotoxin peptides effective in producing analgesia.
Inventor(s): Justice; Alan (Sunnyvale, CA), Singh; Tejinder (Palo Alto, CA), Gohil; Kishor Chandra (Richmond, CA), Valentino; Karen L. (San Carlos, CA), Miljanich; George P. (Redwood City, CA)
Assignee: Elan Pharmaceuticals, Inc. (South San Francisco, CA)
Filing Date:Apr 23, 1999
Application Number:09/298,017
Claims:1. A method of selecting a test compound for producing analgesia, comprising

measuring the activity of the test compound in (i) blocking voltage-gated calcium channels, (ii) binding to the omega conopeptide binding site, and (iii) inhibiting norepinephrine release from nervous tissue; and

selecting the compound for producing analgesia if its activities in (i) blocking voltage-gated calcium channels, (ii) binding to an omega conopeptide binding site, and (iii) inhibiting norepinephrine release from nervous tissue are within the ranges of activities in such assays as measured for omega conopeptides MVIIA/SNX-111, SNX-199, SNX-236, SNX-239 and TVIA/SNX-185.

2. The method of claim 1, wherein said activities in (i) blocking voltage-gated calcium channels, (ii) binding to an omega conopeptide binding site, and (iii) inhibiting norepinephrine release from nervous tissue are within the ranges of activities in such assays as measured for omega-conopeptides MVIIA and TVIA.

3. The method of claim 1, wherein said activity in blocking voltage-gated calcium channels is measured in a whole-cell patch clamp assay using a neuronal cell.

4. The method of claim 3, wherein said neuronal cell is selected from the group consisting of a mouse neuroblastoma cell and a human neuroblastoma cell.

5. The method of claim 1, wherein said binding to the omega conopeptide binding site is measured as a ratio of binding to an MVIIA/SNX-111 binding displacement assay.

6. The method of claim 1, wherein said binding to the omega conopeptide binding site is measured as a ratio of binding to an MVIIA/SNX-111 binding site and to an SVIB/MVIIC binding site.

7. The method of claim 1, wherein said inhibition of norepinephrine release is measured in tissue slices derived from the hippocampal region of mammalian brain.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc